Establishment and Evaluation of Multimodal Image Recognition System of Glioma Based on Deep Learning
Condition:   Glioma Intervention:   Device: PET/CT, H-MRS and MRI Sponsor:   Tao Xin Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 29, 2020 Category: Research Source Type: clinical trials

TAF/FTC for Pre-exposure Prophylaxis of COVID-19 in Healthcare Workers (CoviPrep Study)
Conditions:   Healthcare Workers;   COVID-19;   SARS-CoV 2 Interventions:   Drug: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet;   Drug: Placebo Sponsors:   Hospital Italiano de Buenos Aires;   Sociedad Argentina de Infectología (SADI) (Argentine Society of Infectious Diseases) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 28, 2020 Category: Research Source Type: clinical trials

Characterizing SARS-CoV-2-specific Immunity in Individuals Who Have Recovered From COVID-19
Conditions:   SARS-CoV-2;   COVID-19 Intervention:   Other: Sample collection Sponsors:   HIV Vaccine Trials Network;   National Institute of Allergy and Infectious Diseases (NIAID);   HIV Prevention Trials Network Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 27, 2020 Category: Research Source Type: clinical trials

COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)
Condition:   Corona Virus Disease 2019 Intervention:   Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2020 Category: Research Source Type: clinical trials

Adaptive COVID-19 Treatment Trial 2 (ACTT-II)
Condition:   COVID-19 Interventions:   Other: Placebo;   Drug: Remdesivir;   Drug: Baricitinib Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2020 Category: Research Source Type: clinical trials

COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)
Condition:   Corona Virus Disease 2019 Intervention:   Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2020 Category: Research Source Type: clinical trials

Adaptive COVID-19 Treatment Trial 2 (ACTT-II)
Condition:   COVID-19 Interventions:   Other: Placebo;   Drug: Remdesivir;   Drug: Baricitinib Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2020 Category: Research Source Type: clinical trials

COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)
Condition:   Corona Virus Disease 2019 Intervention:   Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2020 Category: Research Source Type: clinical trials

Adaptive COVID-19 Treatment Trial 2 (ACTT-II)
Condition:   COVID-19 Interventions:   Other: Placebo;   Drug: Remdesivir;   Drug: Baricitinib Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2020 Category: Research Source Type: clinical trials

COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)
Condition:   Corona Virus Disease 2019 Intervention:   Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2020 Category: Research Source Type: clinical trials

Adaptive COVID-19 Treatment Trial 2 (ACTT-II)
Condition:   COVID-19 Interventions:   Other: Placebo;   Drug: Remdesivir;   Drug: Baricitinib Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 26, 2020 Category: Research Source Type: clinical trials

COVID-19 Associated Lymphopenia Pathogenesis Study in Blood (CALYPSO)
Condition:   Corona Virus Disease 2019 Intervention:   Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 25, 2020 Category: Research Source Type: clinical trials

Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine
GAITHERSBURG, Md., May 25, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced enrollment of the first... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - May 25, 2020 Category: Pharmaceuticals Source Type: clinical trials

Efficacy and Safety of COVID-19 Convalescent Plasma
Conditions:   Convalescent Plasma;   COVID-19;   SARS-CoV 2 Intervention:   Biological: anti-SARS-CoV-2 convalescent plasma Sponsors:   Institute for Transfusion Medicine of RNM;   University Clinic for Infectious Diseases, North Macedonia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 22, 2020 Category: Research Source Type: clinical trials

Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND)
Condition:   COVID-19 Intervention:   Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 20, 2020 Category: Research Source Type: clinical trials

Lung Ultrasound Score in Covid 19 Infectious Disease in Critical Care (LUS-COVID19)
Condition:   COVID Intervention:   Procedure: lung ultrasound (LUS) Sponsor:   Centre Hospitalier Universitaire de Nice Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 19, 2020 Category: Research Source Type: clinical trials